About US
Contact us
>>Back
Foreign demand saves Ipsen's primary-care plant
- Publisher：
- Publication：2012/7/13
Ipsen's news isn't all bad these days. After its big plans for a new hemophilia drug hit a big snag earlier this week, the drugmaker is announcing plans to keep a French plant it had slated for sale. The reason: Increasing sales of the primary-care drugs made there.
The plant's 580 workers can thank emerging markets for their reprieve. Demand in these faster-growing markets has bloomed, the company told Reuters. "There's been a change in the economic environment," a spokesman told the news service. "There's been more international volume from countries like China, Russia."
Ipsen's strategy has been in a state of flux. Facing declining demand for its primary care products, the company decided to stake its future on specialty meds. One of those specialty drugs, unfortunately, is the late-stage hemophilia treatment that ran into trouble two days ago, when FDA put a hold on two studies.